This study aims to compare new HIV medications, bictegravir (BIC) and lenacapavir (LEN), with current treatments for people with HIV-1. HIV-1 is a type of virus that attacks the body's immune system. The study is in two phases, with Phase 2 focusing on switching to BIC and LEN, and Phase 3 testing a fixed-dose combination of these drugs. To join the study, participants must have a stable HIV-1 condition, shown by low virus levels in their blood, and be on a complex treatment plan for at least 6 months. A complex plan might mean taking multiple pills daily or having experienced resistance to simpler treatments. Participants should not have used LEN before and shouldn't have certain infections like tuberculosis or hepatitis B.
Key Points:
- Study involves switching current HIV treatment to new medications.
- Participants must have low HIV levels and a complex treatment history.
- Some infections disqualify participation, such as tuberculosis and hepatitis B.
How understandable was the trial content above?
Hard to understand
Easy to understand